Event

Realising the Potential of Transformative Therapies

A European Pharmaceutical Strategy that Enables Safe and Timely Patient Access to Cell and Gene Therapies

Register
30 June 2021
15.00-17.00 CEST
Online

Recent years have seen a number of innovative therapies becoming available to patients in Europe.  ‘Transformative therapies’ – such as cell and gene therapies – bring new hope for the treatment of diseases, with the promise that they not only manage the symptoms of severe, disabling or life-limiting conditions, but transform and save lives. 

On 30 June, the European Alliance for Transformative Therapies launched its Recommendations for Action for Cell and Gene Therapies in the context of the European Pharmaceutical Strategy which have been developed collaboratively with expert stakeholders.

Our speakers explored the opportunities and challenges for innovative therapies in Europe and discussed what policy changes are needed in the forthcoming reviews of the EU pharmaceutical framework to realise the potential for cell and gene therapies, and to ensure safe and timely access for patients.  

Programme

Interventions by several MEPs, including:

Alessandra Moretti
S&D Co-Chair of the TRANSFORM MEP Interest Group
Ondřej Knotek
Renew Europe Co-Chair of the TRANSFORM MEP Interest Group
Dolors Montserrat
EPP MEP, Rapporteur on the EP Pharmaceutical Strategy Report

Panel I: Launch of TRANSFORM Recommendations: Challenges and Opportunities for Transformative Therapies

Simone Boselli
Public Affairs Director, EURORDIS
Dr Pauline Meij
Head of the Cell and Gene Therapy Facility, Leiden University Medical Center
Dr Alexander Natz
Secretary-General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Panel II: The Way Ahead: What is Needed to Solve the Challenges?

Dr Ana Hidalgo-Simon
Head of Advanced Therapies, European Medicines Agency
Dolors Montserrat
EPP MEP, Rapporteur on the EP Pharmaceutical Strategy Report
Dr Gaetano Guglielmi
Deputy Director General for Health Research and Innovation, Italian Ministry of Health

Joint Q&A session between Panel I and II, with participation of TRANSFORM Alliance members

Simone Boselli
Simone Boselli
Public Affairs Director, EURORDIS
Dr Pauline Meij
Dr Pauline Meij
Head of the Cell and Gene Therapy Facility, Leiden University Medical Center
Dr Alexander Natz
Dr Alexander Natz
Secretary-General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Dr Ana Hidalgo-Simon
Dr Ana Hidalgo-Simon
Head of Advanced Therapies, European Medicines Agency
Dolors Montserrat
Dolors Montserrat
EPP MEP, Rapporteur on the EP Pharmaceutical Strategy Report
Dr Gaetano Guglielmi
Dr Gaetano Guglielmi
Deputy Director General for Health Research and Innovation, Italian Ministry of Health
Dr Carmelo Rizzari
Dr Carmelo Rizzari
President-elect and Board Member, the European Society for Paediatric Oncology (SIOP Europe, SIOPE)
Delphine Heenen
Delphine Heenen
European Affairs Lead and Committee Member, Childhood Cancer International – Europe (CCI Europe, CCI-E and KickCancer)
Dr Giovanni Migliaccio
Dr Giovanni Migliaccio
Scientific Director, Consorzio per le Valutazioni Biologiche e Farmacologiche & Member of the Management Team, European Paediatric Translational Research Infrastructure (EPTRI)
Prof Marcela Votruba
Prof Marcela Votruba
Professor of Ophthalmology, Cardiff University & EU EYE Board Member

Moderator

Jacki Davis
Event Memorandum

TRANSFORM – Event Memorandum_30 June_long

Event Memorandum (short 1-pager)

TRANSFORM – Event Memorandum_30 June_shortpdf.

Programme

Download the event programme here.

← Back to events